IV Iron Replacement Therapy to Mitigate the Burden of Iron Deficiency Anemia: Updates for Health-System Pharmacists

This activity was originally presented at the 2022 ASHP Midyear Clinical Meeting & Exposition.

Program Description

Iron deficiency anemia (IDA) occurs when iron deficiency is severe enough to diminish erythropoiesis and cause the development of anemia. IDA, a microcytic anemia is the most common cause of anemia worldwide, and its management includes identification and treatment of the underlying cause, if feasible, and iron supplementation. Though many patients with IDA can be treated with oral iron replacement agents, some cases warrant the use of intravenous (IV) iron, especially in adults who cannot tolerate or absorb oral iron. Pharmacists within health systems and hospitals must recognize risk factors and clinical presentation of IDA. This activity will review the challenges associated with identifying and treating IDA, especially in patient populations at greater risk for health complications. With a greater understanding of available and emerging oral and IV iron formulations, pharmacists will be better equipped to discuss the benefits and risks of each, including efficacy and safety, with patient populations that are ideal candidates for IV iron replacement therapies.

Target audience: Health-system pharmacists

Type of activity: Application
Release date: December 22, 2022
Expiration date: December 22, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore the burden of illness associated with iron deficiency anemia (IDA) including the impact of undiagnosed and untreated IDA
• Examine the safety and efficacy of current intravenous iron preparations, as well as differentiating dosing
• Determine individualized treatment strategies for patients with IDA based on clinical evidence and recommendations